Key result
Switching from pravastatin to simvastatin in warfarin-treated patients is linked to a ~0.3-point higher mean INR.
Observational (n=46)
Answers are grounded in this paper and cite their sources.
Forty-six adult patients maintained on warfarin therapy were converted from pravastatin to simvastatin. Mean international normalized ratio (INR) significantly increased from 2.42 to 2.74, p = 0.002. Although warfarin doses were reduced in 7 patients and increased in 4 patients following the post-conversion INR measurements, the pre- and postconversion median weekly warfarin dose of all 46 patients did not differ significantly. The number of patients with an INR > 3.0 increased significantly from 6 to 16 following the conversion. There was no report of unusual episodes of bleeding. The results indicate that antihyperlipidemic therapy can be changed safely from pravastatin to simvastatin in patients who are taking warfarin concomitantly. Additional anticoagulation monitoring is not necessary in institutions where patients are followed in formal anticoagulation clinics.
No takes yet. Share an insight, caveat, or question.
Lin et al. (1999) conducted an observational in Hyperlipidemia and anticoagulation with warfarin (n=46). Conversion from pravastatin to simvastatin vs. Pre-conversion pravastatin therapy was evaluated on Mean international normalized ratio (INR) (p=0.002). Converting from pravastatin to simvastatin in patients on warfarin increased mean INR from 2.42 to 2.74 without causing unusual bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: